Compare BNZI & INBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BNZI | INBS |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | 34 | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7M | 5.7M |
| IPO Year | N/A | 2019 |
| Metric | BNZI | INBS |
|---|---|---|
| Price | $3.49 | $2.47 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $24.00 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 171.9K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 68.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,980,484.00 |
| Revenue This Year | $41.28 | $778.48 |
| Revenue Next Year | $0.92 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $0.54 |
| 52 Week High | $8.10 | $24.90 |
| Indicator | BNZI | INBS |
|---|---|---|
| Relative Strength Index (RSI) | 52.00 | 41.18 |
| Support Level | $0.84 | $2.33 |
| Resistance Level | $3.51 | $3.16 |
| Average True Range (ATR) | 1.06 | 0.44 |
| MACD | -0.22 | -0.07 |
| Stochastic Oscillator | 5.56 | 2.50 |
Banzai International Inc is a Software as a Service (SaaS) company operating in the marketing technology (MarTech) industry. The group provides customers with tools to help them market and sell with greater efficiency and impact. Its customers include Amazon, Dell, Salesforce, Aflac, Thermo Fisher Scientific, RBC Wealth Management, Fitch Group, and many other brands. The Company has three reportable operating segments: Banzai Operating Co, Inc., OpenReel, and Vidello. Its segments deliver SaaS tools that leverage data, analytics, and AI to provide marketing and sales solutions, including video production and editing, for businesses of all sizes. Geographically, it operates in the Americas, Europe, the Middle East and Africa (EMEA), and the Asia Pacific.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.